Prospective, Multi-country, Non-interventional, Case-control with Test- negative Controls to Estimate the Effectiveness of the Ad26.ZEBOV, MVA-BN-Filo Vaccine Regimen Against Ebola Virus Disease in Real-world Setting (v2.0, 23 January 2024)

Start Date05 Jan 2025

Sponsor / Collaborator

Janssen Research & Development LLC

NCT06549530 / Not yet recruitingPhase 2

Open-label, Multicenter Immunogenicity and Safety Study of MVA-BN Vaccine in Children From 2 Years to Less Than 12 Years of Age Compared to Adults for the Prevention of Smallpox, Mpox, and Related Orthopoxvirus Infections

All participants will receive 2 vaccinations of the same dose of Modified Vaccinia Ankara Virus (MVA-BN) vaccine 4 weeks apart (standard regimen).
Serum samples for assessment of immune response will be collected at baseline (visit of first vaccination) and at 2 weeks (week 6), 6 months (week 30), and 1 year after the second (last) vaccination.

Start Date16 Oct 2024

Sponsor / Collaborator

Bavarian Nordic A/S

[+1]

PACTR202306534727467 / RecruitingPhase 2IIT

A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral-Vectored Marburg Virus Vaccine in Healthy Adults

Start Date26 Sep 2023

Sponsor / Collaborator-

100 Clinical Results associated with MVA-BN-Filo(Bavarian Nordic, Crucell)

100 Translational Medicine associated with MVA-BN-Filo(Bavarian Nordic, Crucell)

100 Patents (Medical) associated with MVA-BN-Filo(Bavarian Nordic, Crucell)

Literatures (Medical) associated with MVA-BN-Filo(Bavarian Nordic, Crucell)

31 Dec 2024·Human Vaccines & Immunotherapeutics

Lot-to-lot consistency, immunogenicity, and safety of the Ad26.ZEBOV, MVA-BN-Filo Ebola virus vaccine regimen: A phase 3, randomized, double-blind, placebo-controlled trial

Article

Author: Hendriks, Jenny ; Doua, Joachim ; Keshinro, Babajide ; Bus-Jacobs, Linda ; Robinson, Cynthia ; McLean, Chelsea ; Luhn, Kerstin ; Douoguih, Macaya ; Gaddah, Auguste ; Goldstein, Neil

This phase-3, double-blind, placebo-controlled study (NCT04228783) evaluated lot-to-lot consistency of the Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine regimen. Participants were randomized (6:6:6:1) to receive the two-dose regimen from three consecutively manufactured lots of Ad26.ZEBOV on Day 1 paired with three consecutively manufactured lots of MVA-BN-Filo on Day 57 (Groups 1-3) or two doses of placebo (Group 4). An additional cohort also received an Ad26.ZEBOV booster or placebo 4 months post-dose 2. Equivalence of the immunogenicity at 21 days post-dose 2 between any two groups was demonstrated if the 95% confidence interval (CI) of the Ebola virus glycoprotein (EBOV GP)-binding antibody geometric mean concentration (GMC) ratio was entirely within the prespecified margin of 0.5-2.0. Lot-to-lot consistency (i.e., consecutive lots can be consistently manufactured) was accomplished if equivalence was shown for all three pairwise comparisons. Results showed that the primary objective in the per-protocol immunogenicity subset (n = 549) was established for each pairwise comparison (Group 1 vs 2: GMC ratio = 0.9 [95% CI: 0.8, 1.1], Group 1 vs 3: 0.9 [0.8, 1.1], Group 2 vs 3: 1.0 [0.9, 1.2]). Equivalence of the three groups for the Ad26.ZEBOV component only was also demonstrated at 56 days post-dose 1. EBOV GP-binding antibody responses (post-vaccination concentrations >2.5-fold from baseline) were observed in 419/421 (99.5%) vaccine recipients at 21 days post-dose 2 and 445/460 (96.7%) at 56 days post-dose 1. In the booster cohort (n = 39), GMCs increased 9.0- and 11.8-fold at 7 and 21 days post-booster, respectively, versus pre-booster. Ad26.ZEBOV, MVA-BN-Filo was well tolerated, and no safety issues were identified.

01 Jul 2024·The Lancet Infectious Diseases

Ad26.ZEBOV, MVA-BN-Filo Ebola virus disease vaccine regimen plus Ad26.ZEBOV booster at 1 year versus 2 years in health-care and front-line workers in the Democratic Republic of the Congo: secondary and exploratory outcomes of an open-label, randomised, phase 2 trial

Article

Author: Matuvanga, Trésor Zola ; Robinson, Cynthia ; Meta, Rachel ; Osang'ir, Bernard Isekah ; McLean, Chelsea ; Maketa, Vivi ; Van Damme, Pierre ; Kimbulu, Primo ; Milolo, Solange ; Katwere, Michael ; Larivière, Ynke ; Muhindo-Mavoko, Hypolite ; Van Geertruyden, Jean-Pierre ; Mitashi, Patrick ; Lemey, Gwen ; Matangila, Junior

BACKGROUNDHealth-care providers and front-line workers are at risk of contracting Ebola virus disease during an Ebola virus outbreak and consequently of becoming drivers of the disease. We aimed to assess the long-term immunogenicity of the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen and the safety of and immune memory response to an Ad26.ZEBOV booster vaccination at 1 year or 2 years after the first dose in this at-risk population.METHODSThis open-label, single-centre, randomised, phase 2 trial was conducted at one study site within a hospital in Boende, Democratic Republic of the Congo. Adult health-care providers and front-line workers, excluding those with a known history of Ebola virus disease, were vaccinated with a two-dose heterologous regimen administered at a 56-day interval via a 0·5 mL intramuscular injection in the deltoid muscle, comprising Ad26.ZEBOV as the first dose and MVA-BN-Filo as the second dose. After the initial vaccination on day 1, participants were randomly assigned (1:1) via randomisation envelopes, opened in a sequential order, to receive an Ad26.ZEBOV booster vaccination at 1 year (group 1) or 2 years (group 2) after the first dose. We present the secondary and exploratory objectives of the trial-results of the primary objective have been published elsewhere. We measured immunogenicity at six timepoints per group as geometric mean concentrations (GMCs) of Ebola virus glycoprotein-specific IgG binding antibodies, using the Filovirus Animal Non-Clinical Group ELISA. We assessed serious adverse events occurring up to 6 months after the last dose and local and systemic solicited and unsolicited adverse events reported for 7 days after the booster vaccination. Antibody responses were analysed per protocol, serious adverse events per full analysis set (FAS), and adverse events for all boosted FAS participants. This trial is registered as completed on ClinicalTrials.gov (NCT04186000).FINDINGSBetween Dec 18, 2019, and Feb 8, 2020, 699 health-care providers and front-line workers were enrolled and 698 were randomly assigned (350 to group 1 and 348 to group 2 [FAS]); 534 (77%) participants were male and 164 (23%) were female. 319 in group 1 and 317 in group 2 received the booster. 29 (8%) in group 1 and 26 (7%) in group 2 did not complete the study, mostly due to loss to follow-up or moving out of the study area. In both groups, injection-site pain or tenderness (87 [27%] of 319 group 1 participants vs 90 [28%] of 317 group 2 participants) and headache (91 [29%] vs 93 [29%]) were the most common solicited adverse events related to the investigational product. One participant (in group 2) had a related serious adverse event after booster vaccination (fever of ≥40·0°C). Before booster vaccination, Ebola virus glycoprotein-specific IgG binding antibody GMCs were 279·9 ELISA units (EU) per mL (95% CI 250·6-312·7) in 314 group 1 participants (1 year after first dose) and 274·6 EU/mL (242·1-311·5) in 310 group 2 participants (2 years after first dose). These values were 5·2 times higher in group 1 and 4·9 times higher in group 2 than before vaccination on day 1. 7 days after booster vaccination, these values increased to 10 781·6 EU/mL (9354·4-12 426·4) for group 1 and 10 746·9 EU/mL (9208·7-12 542·0) for group 2, which were approximately 39 times higher than before booster vaccination in both groups. 1 year after booster vaccination in 299 group 1 participants, a GMC that was 7·6-times higher than before booster vaccination was still observed (2133·1 EU/mL [1827·7-2489·7]).INTERPRETATIONOverall, the vaccine regimen and booster dose were well tolerated. A similar and robust humoral immune response was observed for participants boosted 1 year and 2 years after the first dose, supporting the use of the regimen and flexibility of booster dose administration for prophylactic vaccination in at-risk populations.FUNDINGInnovative Medicines Initiative 2 Joint Undertaking and Coalition for Epidemic Preparedness Innovations.

12 Apr 2024·The Journal of Infectious Diseases

Safety and Immunogenicity of the Heterologous 2-Dose Ad26.ZEBOV, MVA-BN-Filo Vaccine Regimen in Health Care Providers and Frontliners of the Democratic Republic of the Congo

Article

Author: Katwere, Michael ; Muhindo-Mavoko, Hypolite ; Garcia-Fogeda, Irene ; Zola Matuvanga, Trésor ; McLean, Chelsea ; Mitashi, Patrick ; Milolo, Solange ; Kimbulu, Primo ; Maketa, Vivi ; Robinson, Cynthia ; Meta, Rachel ; Matangila, Junior ; Van Damme, Pierre ; Larivière, Ynke ; Van geertruyden, Jean-Pierre ; Isekah Osang'ir, Bernard ; Hens, Niel

AbstractBackgroundIn response to recent Ebola epidemics, vaccine development against the Zaire ebolavirus (EBOV) has been fast-tracked in the past decade. Health care providers and frontliners working in Ebola-endemic areas are at high risk of contracting and spreading the virus.MethodsThis study assessed the safety and immunogenicity of the 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo vaccine regimen (administered at a 56-day interval) among 699 health care providers and frontliners taking part in a phase 2, monocentric, randomized vaccine trial in Boende, the Democratic Republic of Congo. The first participant was enrolled and vaccinated on 18 December 2019. Serious adverse events were collected up to 6 months after the last received dose. The EBOV glycoprotein FANG ELISA (Filovirus Animal Nonclinical Group enzyme-linked immunosorbent assay) was used to measure the immunoglobulin G–binding antibody response to the EBOV glycoprotein.ResultsThe vaccine regimen was well tolerated with no vaccine-related serious adverse events reported. Twenty-one days after the second dose, an EBOV glycoprotein–specific binding antibody response was observed in 95.2% of participants.ConclusionsThe 2-dose vaccine regimen was well tolerated and led to a high antibody response among fully vaccinated health care providers and frontliners in Boende.

News (Medical) associated with MVA-BN-Filo(Bavarian Nordic, Crucell)

29 Oct 2024

·www.globenewswire.com

First Children Vaccinated in New Clinical Study Seeking to Expand the Indication for Bavarian Nordic’s Mpox Vaccine

Clinical study in children 2-11 years of age follows the recent EMA and WHO approvals of the MVA-BN mpox vaccine for adolescents 12-17 of age. COPENHAGEN, Denmark, October 29, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today the initiation of a clinical study of the MVA-BN® mpox/smallpox vaccine in children 2 to 11 years of age. The first children have now been vaccinated in the study, which is currently enrolling in the Democratic Republic of Congo (DRC) with plans also to include sites in Uganda. A total of 460 individuals are expected to participate in the study, which will compare the safety and immunogenicity of the vaccine between children aged 2 to 11 years of age to adults. The study (NCT06549530) is partially funded by the Coalition for Epidemic Preparedness Innovations (CEPI). Results from this study could support an extension of the current approval of MVA-BN to include children from 2 years of age and older. Last month, the WHO prequalified the vaccine for adolescents 12 to 17 years of age, adopting the recent approval from the European Medicines Agency (EMA) for this age group. Paul Chaplin, President & CEO of Bavarian Nordic, said: “Children remain highly vulnerable to mpox infections in the ongoing outbreak in Africa, highlighting the importance and urgency to broaden the access to effective vaccines that can be safely administered to this young population. Following the recent approval of MVA-BN for adolescents, we are pleased to initiate this study, which could provide additional data to further extend the indication to also include children, and we thank CEPI and our partners in Africa for their support of this important work.” Dr Nicole Lurie, Executive Director of Preparedness and Response at CEPI, said: “The findings of this study will be crucial in shaping mpox vaccine strategies that could protect children and bring an end to this devastating and widespread outbreak, while also providing pivotal vaccine guidance in local endemic populations to tackle mpox outbreaks that could strike in the future.” While this study represents the first investigation of MVA-BN as an mpox/smallpox vaccine for younger children, a recombinant version of MVA-BN (Mvabea®) was approved by EMA in 2020 as part of a prime-boost vaccine regimen1 for the prevention of disease caused by Ebola virus in individuals 1 year of age and older. Clinical studies supporting this approval encompassed more than 3,300 individuals across Europe, USA, and Africa including over 800 children and adolescents 1 to 17 years of age in Africa2. The safety profile of Mvabea in children 1 to 17 years of age was generally similar to that observed in adults. About the mpox vaccineMVA-BN or Modified Vaccinia Ankara-Bavarian Nordic is the only non-replicating mpox vaccine approved in the U.S., Switzerland, Singapore and Mexico (marketed as JYNNEOS®), Canada (marketed as IMVAMUNE®), and the EU/EAA and United Kingdom (marketed as IMVANEX®). Originally developed as a smallpox vaccine in collaboration with the U.S. government to ensure the supply of a smallpox vaccine for the entire population, including immunocompromised individuals who are not recommended vaccination with traditional replicating smallpox vaccines, MVA-BN has been indicated for use in the general population (from 12 years old) in individuals considered at risk for smallpox or mpox infection. About Bavarian NordicBavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and have a leading portfolio of travel vaccines. For more information, visit www.bavarian-nordic.com. Forward-looking statements This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law. ContactsEurope: Rolf Sass Sørensen, Vice President Investor Relations, rss@bavarian-nordic.com, Tel: +45 61 77 47 43US: Graham Morrell, Paddock Circle Advisors, graham@paddockcircle.com, Tel: +1 781 686 9600 1 Mvabea® was licensed in 2014 to Johnson & Johnson as part of a prime-boost vaccine regimen. 2 https://www.ema.europa.eu/en/documents/assessment-report/mvabea-epar-public-assessment-report_en.pdf Attachment 2024-10-29-en

Drug ApprovalVaccineClinical Study

29 Oct 2024

·www.pharmaceutical-technology.com

Bavarian eyes Mpox vaccine label expansion to include toddlers, kickstarts Phase II trial

MVA-BN is marketed as Jynneos in the US and as Imvanex in Europe. Image credit: Sonia Bonet / Shutterstock. Bavarian Nordic is looking to expand the approval label of its MVA-BN mpox/smallpox vaccine to include children two to 11 years of age and has started a Phase II trial to support the approval. The Phase II study (NCT06549530) plans to compare the safety and immunogenicity of the vaccine between children in that age group to adults. The trial is partially funded by the Coalition for Epidemic Preparedness Innovations (CEPI). The Danish vaccine company intends to recruit participants across the Democratic Republic of Congo and potentially Uganda. The World Health Organization (WHO) declared mpox a global public health emergency for the second time in two years in August after a new type of the virus spread from the Democratic Republic of Congo to neighbouring countries. MVA-BN is a non-replicating mpox vaccine. It is marketed as Jynneos in the US and as Imvanex in Europe. In September, the European Medicines Agency (EMA) expanded the vaccine label to include adolescents over 12 years of age. The same month, the Global Alliance for Vaccines and Immunization (GAVI) entered into a purchase agreement with Bavarian Nordic to secure 500,000 doses for countries in Africa. Bavarian Nordic noted that whilst the Phase II trial marks the first investigation of MVA-BN as an mpox/smallpox vaccine for younger children, a recombinant version of the vaccine, Mvabea, was approved by the EMA in 2020 as part of a prime-boost vaccine regimen for the prevention of disease caused by Ebola virus in individuals one year of age and older. See Also: Bladder cancer diagnoses to top 300,000 in major markets by 2033 Biogen and Neomorph enter molecular glue degrader deal “The findings of this study will be crucial in shaping mpox vaccine strategies that could protect children and bring an end to this devastating and widespread outbreak, while also providing pivotal vaccine guidance in local endemic populations to tackle mpox outbreaks that could strike in the future,” said Dr Nicole Lurie, executive director of preparedness and response at CEPI. The mpox/smallpox vaccine has been a major revenue driver for Bavarian Nordic. The vaccine generated DKK5bn ($724m) in revenue from global vaccine sales and government contracts last year, as per the company’s financials. Another mpox vaccine in development is Moderna ’s mRNA vaccine, currently being trialled in a Phase I/II study (NCT05995275). The trial is evaluating the safety, tolerability, and immunogenicity of mRNA-1769 in healthy adults.

VaccinePhase 2Drug Approval

19 Sep 2024

·www.pharmaceutical-technology.com

Gavi to obtain 500,000 mpox vaccine doses from Bavarian Nordic

Bavarian Nordic recently made a filing with the European Medicines Agency seeking to extend the vaccine’s approval to adolescents. Credit: angellodeco/Shutterstock. Gavi (the Global Alliance for Vaccines and Immunization) has entered an advance purchase agreement with Bavarian Nordic to secure 500,000 doses of the modified vaccinia Ankara-Bavarian Nordic (MVA-BN) mpox vaccine. The vaccines, marketed under names including JYNNEOS and IMVANEX, are intended for supply in African countries. Scheduled for delivery in 2024, the vaccines are financed by Gavi’s First Response Fund, a new emergency funding mechanism designed to expedite vaccine procurement during health crises. The MVA-BN vaccine, which received WHO prequalification on 13 September 2024, will be supplied pending a supply agreement with UNICEF, Gavi’s alliance partner responsible for distribution. The APA follows the delivery of 250,000 doses of Bavarian Nordic vaccines to the Democratic Republic of the Congo (DRC), donated by various countries and Bavarian Nordic itself. See Also: GC Therapeutics secures $65m to launch into off-the-shelf iPSC therapy space Sanofi eyes approval after MS therapy slows disease progression by 31% The allocation of these doses follows WHO’s Access and Allocation Mechanism guidelines, ensuring they reach those most in need. The MVA-BN vaccine is the only non-replicating mpox vaccine approved in Canada, the EU, Singapore, Switzerland, the UK and the US. Initially developed as a smallpox vaccine for immunocompromised individuals, it is now indicated for adults at risk for smallpox or mpox. Bavarian Nordic recently made a filing with the European Medicines Agency seeking to extend the vaccine’s approval to adolescents aged 12 to 17. The company is also evaluating the vaccine’s safety and efficacy in children aged two to 12, in collaboration with partners such as the Coalition for Epidemic Preparedness Innovations (CEPI). Bavarian Nordic president and CEO Paul Chaplin stated: “We are pleased to sign this agreement and strengthen our commitment to support Gavi and other global health partners, who have demonstrated strong leadership in making life-saving vaccines available for the vulnerable populations in developing countries for decades. “The doses secured through this agreement will significantly increase the availability of mpox vaccines for African countries, and we are pleased that Gavi has selected our MVA-BN vaccine, which has proven highly effective during the global mpox outbreak in 2022.” Bavarian Nordic recently announced plans to prioritise the production of two million mpox vaccines by the end of 2024 to help fight the disease in Africa.

Vaccine

100 Deals associated with MVA-BN-Filo(Bavarian Nordic, Crucell)

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	J07BX	-

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Hemorrhagic Fever, Ebola	EU	Janssen-Cilag International NV	01 Jul 2020
Hemorrhagic Fever, Ebola	NO	Janssen-Cilag International NV	01 Jul 2020
Hemorrhagic Fever, Ebola	IS	Janssen-Cilag International NV	01 Jul 2020
Hemorrhagic Fever, Ebola	LI	Janssen-Cilag International NV	01 Jul 2020

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Marburg Virus Disease	Preclinical	US	National Institute of Allergy & Infectious Diseases	24 Mar 2017
HIV Infections	Preclinical	CI	Janssen Vaccines & Prevention BV	06 Nov 2015
HIV Infections	Preclinical	UG	Janssen Vaccines & Prevention BV	06 Nov 2015
HIV Infections	Preclinical	KE	Janssen Vaccines & Prevention BV	06 Nov 2015
HIV Infections	Preclinical	BF	Janssen Vaccines & Prevention BV	06 Nov 2015
Hemorrhagic Fever, Ebola	Preclinical	SL	Janssen Vaccines & Prevention BV	30 Sep 2015
Hemorrhagic Fever, Ebola	Preclinical	SL	Janssen Vaccines & Prevention BV	30 Sep 2015

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02661464 (CTgov)	Phase 3	Hemorrhagic Fever, Ebola	677	MVA-BN-Filo+Ad26.ZEBOV (Cohort 1: Ad26.ZEBOV + MVA-BN-Filo)	xtutrjqfyo(bikeanubaa) = oxyqtzkgsu sphlqubwkq (ieaednwuwy, ykevlihkml - ehhpzqmsbk) View more	-	02 Jan 2024
				placebo+MVA-BN-Filo+Ad26.ZEBOV (Cohort 1: Placebo)	xtutrjqfyo(bikeanubaa) = mgnjjmcrpc sphlqubwkq (ieaednwuwy, gzttijmqpo - jlhxnwwvmg) View more
PACTR201905827924069 \| NCT03929757 (CTgov)	Phase 2	Hemorrhagic Fever, Ebola	108	MVA-BN-Filo+Ad26.ZEBOV (Main Study: Ad26.ZEBOV + MVA-BN-Filo + MenACWY)	emnujshayc(xgemmxlkoa) = qxltjfoimm wmowmtekmb (qkpdjffinv, wqpahrjdrx - ssbffmztzm) View more	-	22 Jun 2023
				MenACWY vaccine (Main Study: MenACWY (Control Arm))	emnujshayc(xgemmxlkoa) = gbzzamejaq wmowmtekmb (qkpdjffinv, pofjbagiqv - lmnpzcedhv) View more
NCT04228783 (CTgov)	Phase 3	Hemorrhagic Fever, Ebola	974	MVA-BN-Filo+Ad26.ZEBOV (Ad26.ZEBOV(Lot A), MVA-BN-Filo (Lot 1) (Group 1))	rmffeiuerp(xdgyogilkf) = hoysipqqpe nuyzlbifwk (biiknmcjct, hlyadxyoji - qbuvasrxwb) View more	-	17 May 2023
				MVA-BN-Filo+Ad26.ZEBOV (Ad26.ZEBOV(Lot B), MVA-BN-Filo (Lot 2) (Group 2))	rmffeiuerp(xdgyogilkf) = czyjbmgexb nuyzlbifwk (biiknmcjct, tgprccliks - jqjnqhhxqa) View more
NCT02509494 (EBOVAC-Salone, CTgov)	Phase 3	Hemorrhagic Fever, Ebola	1,023	MVA-BN-Filo (Ad26.ZEBOV)+Ad26.ZEBOV (Stage 1 (>=18 Years): Ad26.ZEBOV, MVA-BN-Filo (Ad26.ZEBOV))	qrxwjhmldq(dhkwlxyjop) = ivaopdessa voeuthvwvf (zuxtbzrmhw, zeqdkvhhai - qyimyosbyd) View more	-	18 Jul 2022
				MVA-BN-Filo+Ad26.ZEBOV (Stage 2 (>=18 Years): Ad26.ZEBOV, MVA-BN-Filo)	qrxwjhmldq(dhkwlxyjop) = nyauulxzdg voeuthvwvf (zuxtbzrmhw, rriucjltzh - ydqxksqohx) View more
NCT02509494 (EBOVAC-Salone, Pubmed) Manual	Phase 2	Hemorrhagic Fever, Ebola	443	Ad26.ZEBOV+MVA-BN-Filo	(kumaroccfi) = In stage 1, solicited local adverse events (mostly mild or moderate injection-site pain) were reported in 12 (28%) of 43 participants after Ad26. In stage 2, solicited local adverse events were reported in 51 (17%) of 298 participants after Ad26. ugatjvltqu (ngtsjwdexo ) View more	Positive	01 Jan 2022
				MenACWY+Placebo
NCT03583606 (CTgov)	Phase 1	Hemorrhagic Fever, Ebola	61	Placebo+ChAd3-EBO-Z (ChAd3-EBO-Z + Placebo)	tcosfekykt(aqrhmwssqv) = vibirefipj mrjjehgcui (muxbmixmis, haimichxvb - adsweewqvv) View more	-	02 Jun 2021
				ChAd3-EBO-Z (ChAd3-EBO-Z + ChAd3-EBO-Z)	tcosfekykt(aqrhmwssqv) = djjseyorxs mrjjehgcui (muxbmixmis, nzbctqwzeq - xxbxehvmyd) View more
NCT02416453 (EBOVAC2, Pubmed \| Lancet Infect Dis) Manual	Phase 2	Hemorrhagic Fever, Ebola	423	Placebo+Ad26.ZEBOV+MVA-BN-Filo	(xtvoyiuida) = 255 (77%) Ad26.ZEBOV vaccinations, 116 (49%) MVA-BN-Filo vaccinations, and 33 (46%) placebo injections, and included mostly mild or moderate fatigue, headache, or myalgia. koxpxqnlfg (uhiwdmtpqt )	Positive	01 Apr 2021

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis